Loading...
Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disorder, and yet with no pharmacological treatment approved worldwide. The repositioning of old drugs provides a safe approach for drug development. Vidofludimus, an inhibitor for dihydroorotate dehydrogenase (DHODH)...
Na minha lista:
| Udgivet i: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7240069/ https://ncbi.nlm.nih.gov/pubmed/32477115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00590 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|